NASDAQ · PHARMACEUTICAL PREPARATIONS
Genelux Corporation GNLX
4 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$8,000
▲ 0.0% vs FY2024
EPS · FY25
$-0.86
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-170.0%
Net margin · FY25
-401812.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 8,000.00
Revenue, FY2025 · full 4-year series below
Revenue
Net income
The company lost 401812 cents on every revenue dollar this year.
Per share
USD -0.86
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-170.0%
Return on equity, FY2025
ROE
Operating margin-415175.0%
Net margin-401812.5%
Return on assets-119.6%
Each USD of equity lost 170 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−91.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.04B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 19.0M
total assets, end of FY2025
Total assetsUSD 19.0M
EquityUSD 11.5M
CashUSD 5.3M
Current ratio2.43×
Equity funds 61% of total assets.
History
4 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
Revenue $B
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
Income tax $B
·
·
·
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.86
−0.95
−1.16
−0.57
Dividend / sh $
·
·
·
·
Payout %
·
·
·
·
ROE %
−170.0
−130.6
·
·
Shares out B
0.04
0.03
0.03
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
12 of 12
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed